111111111111111111111111111111111111111111111111111111111111111111111111111111111
Health
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
A Decade-Long Commitment to the Treatment of Cancer
We have commemorated World Cancer Day.
Egis Strengthens European Presence in the Biosimilar Area
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
A Journey to the Empire of Health: Focusing on Children
This March marks the official start of the Hungarian Nationwide Public Health Screening Program’s special campaign: the new initiative focuses on children’s health.
To Lead a Long and Healthy Life
Health means more than just the lack of illnesses.
Other channels
Egis' products are sold to 100 countries.
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
In the 2022/2023 business year, we spent EUR 48 million on research and development
Healthcare and sharing knowledge are in the heart of our CSR activities
Our highlighted past and future events you shouldn't miss
Quick news
Your browser is out of date. Please, use an updated version!